Tribunal denies duty exemption for therapeutic IV fluids; rectification request dismissed.

The Tribunal dismissed the appellant's application seeking rectification of mistakes in the Final Order, which denied exemption for specific intravenous fluid formulations. The Tribunal upheld its decision that intravenous fluids with therapeutic value would not qualify for duty exemption. It clarified that if the appellant's formulations were solely for replenishment purposes without therapeutic components, exemption could be claimed through excise authorities without rectification. The Tribunal also noted that matters related to Cenvat credit and cum-duty benefit were beyond the scope of the remand order and did not require directions in the Final Order.

---

---

Issues:
Rectification of mistakes apparent from the record under Section 35C(2) of the Central Excise Act, 1944 regarding the denial of exemption for certain intravenous fluid formulations under Notification No. 3/2001 and No. 6/2002-C.E.

Analysis:
The appellant filed an application seeking rectification of mistakes in the Final Order passed by the Tribunal, which dismissed the appeals and upheld the denial of exemption for specific intravenous fluid formulations. The appellant argued that the products in question were meant for replenishment of sugar, electrolyte, or fluids and did not contain antibiotics or other therapeutic components. The appellant also raised concerns about the lack of consideration of certain qualifications and alternative pleas in the impugned order.

The Department Representative opposed the rectification plea, stating that there were no apparent mistakes in the order and that the application resembled an appeal reiterating issues already decided by the Tribunal. After hearing both sides, the Tribunal examined the submissions and records. The Final Order was passed following the Apex Court's directive for a de novo decision on the eligibility of intravenous fluids for duty exemption. The Tribunal considered the therapeutic value of the ingredients in the appellant's products and concluded that those with therapeutic value would not qualify for exemption.

The Tribunal highlighted the distinction between intravenous injections and intravenous fluids under the Drugs and Cosmetics Act, emphasizing that fluids were covered by Schedule 'C'. The Tribunal's decision aligned with the parameters set by the Apex Court's judgment. It was clarified that if certain intravenous formulations by the appellant were solely for replenishment purposes without therapeutic components, the appellant could claim exemption through the excise authorities without the need for rectification.

Regarding the appellant's plea for Cenvat credit and cum-duty benefit, the Tribunal explained that such matters were beyond the scope of the Apex Court's remand order and did not warrant directions in the Final Order. Consequently, the Tribunal found no apparent mistakes in the record and dismissed the application for rectification.

---